BDB. Debuire

B. Debuire

*This is an algorithmically generated author record based on publicly available information.

B. Debuire has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    S22 * YOUNG RESEARCHER SYMPOSIUM II: PATHOGENETIC MECHANISMS OF ALCOHOLIC ASSOCIATED ORGAN INJURY * S22.1 * IRON METABOLISM IN PATIENTS WITH ALD

    by I. Ganzleben, H. Seitz, S. Mueller, G. Millonig, A. Helminen, M. Salaspuro, S. Vakevainen, K. Breitkopf-Heinlein, H. Gaitantzi, C. Meyer, et al.

    Background. Alcoholic liver disease (ALD) is the major liver disease in the developed world that is characterized by pathological hepatic iron deposits. This non-HFE-related iron overload is considered a key mechanism of rapid disease progression towards liver cirrhosis and hepatocellular carcinoma. We here performed a systematic histological, protein and mRNA expression analysis on liver biopsies from patients with well-characterized ALD. Methods. A total of 100 patients with histologically confirmed ALD who were admitted for alcohol withdrawal were included. Clinical parameters, liver biopsies and serum iron parameters were collected. Routine histology and iron content were assessed by H&E and Prussian Blue staining, respectively. We then selected 30 liver biopsies (10 without and 20 with iron overload) for RNA isolation, reverse transcription and quantitative real-time PCR analysis for iron metabolism genes (among them hepcidin, transferrin receptor 1, ferroportin, transferrin, ferritin light and heavy chain, HO-1). In addition, liver sections were stained immunohistochemically for ferritin, ferroportin, transferrin receptor 1 and 2 and HO-1. Results. In our cohort, 50% of patients had iron overload in liver biopsy. Iron overload was mild to moderate partly found in hepatocytes and macrophages. Although serum ferritin rapidly decreases during alcohol detoxification, the initial serum–ferritin concentration showed a significant difference between those patients with and without iron overload (P = 0.02). Despite the difference in liver iron content and serum-ferritin among the two groups of ALD patients, there was no significant regulation in iron metabolism-associated genes at the RNA level. Immunohistochemistry revealed distinct and individual staining patterns for ferritin, ferroportin, TfR1 and TfR2. The intensity, however, did not correlate with Prussian Blue staining. Conclusion. Serum-ferritin is an indicator of iron overload in ALD despite its rapid decrease during alcohol withdrawal. However, absolute and spatial expression of key iron-related proteins is not correlated to iron deposits in the form of hemosiderin or ferritin.

    • 26 November 2004
      • Vol. 62  (6) , 649-56

    [Molecular biology and hepatocellular carcinoma: current status and future prospects].

    by R Saffroy, P Pham, A Lemoine, B Debuire

    Hepatocellular carcinoma (HCC) is among the fifth most common cancers worldwide. Its incidence is still rising in part because of the high level of hepatitis C virus infection. Tumor markers currently used such as serum alpha-foetoprotein are not sufficient for diagnosis of the tumor and satisfying follow-up of the patients. Mechanisms of hepatocarcinogenesis ar not completely understood although several altered genes have been described in HCC. The genetic changes involved can be divided in at least 4 different pathways, each pathway contributing to a limited number of tumors. These are: 1) the p53 pathway involved in response to DNA damage, 2) the retinoblastoma pathway involved in the control of the cell cycle, 3) the transforming growth factor-beta (TGF-beta) pathway involved in growth inhibition, and 4) the Wnt pathway involved in cell-cell adhesion and signal transduction. Alterations of the epigenetic regulation of gene expression have also been described. Evolution of molecular biology methods tends to the development of more global genomic approaches; microsatellite instability analysis, chromosomal instability analysis or gene expression profile analysis have been used to investigate HCC. Finally, attempts to develop molecular biomarkers based on peripheral blood analysis more easily accessible in clinical routine patients have also been developed.


  • Real-time quantitation of bcr-abl transcripts in haematological malignancies

    by R. Saffroy, A. Lemoine, P. Brezillon, N. Frenoy, B. Delmas, E. Goldschmidt, B. Souleau, G. Nedellec, B. Debuire

    We have applied an automated real‐time quantitative PCR assay using a double‐labeled fluorogenic probe to detect t(9;22)‐positive cells in haematological malignancies. The results are expressed as the ratio of chimeric bcr‐abl transcripts on abl transcripts. Highly reproducible results were obtained for t(9;22)‐positive K562 RNA. Ten copies of bcr‐abl DNA from a recombinant KW‐3 plasmid and one positive cell in 104 can be detected. Thirty‐two patients with chronic myeloid leukaemia (CML), 25 with acute leukaemia, 12 with myelodysplastic syndromes and 7 with other myeloproliferative syndromes were tested. Follow‐up data were obtained in bcr‐abl positive cases. Results were compared with those of conventional nested RT‐PCR and cytogenetics. Real‐time quantitative RT‐PCR values correlated well with both these methods. However, in some cases the only means of detecting early relapse or blastic transformation was to examine the kinetics of real‐time quantitative RT‐PCR. Thus, real‐time quantitative RT‐PCR appears suitable for the diagnosis and follow‐up of patients with the t(9;22) translocation.


    • 1 November 1999
      • Vol. 47  (9) , 903-10

    [Hepatocellular carcinoma].

    by A Lemoine, D Azoulay, M Jezequel-Cuer, B Debuire

    Hepatocellular carcinoma is a rapidly fatal tumor that usually becomes symptomatic only at a stage beyond the reach of currently available treatments. The only hope for a cure lies in early diagnosis. It follows that an effective screening strategy should be used in high-risk populations, including patients with cirrhosis due to any cause, patients with chronic hepatitis B or C, and asymptomatic carriers of the B virus genome (and probably the C virus genome). Screening currently relies on physical examination and on two investigations, ultrasound scanning and the alpha-fetoprotein (AFP) assay, whose sensitivity and specificity vary with tumor size. The optimal interval between evaluations seems to be four to six months, although large prospective studies confirming this are not yet available. Because the AFP assay lacks sensitivity and specificity in patients with small tumors, other serum markers are being evaluated. In parallel, hepatitis B immunization and alpha interferon therapy of chronic hepatitis C are expected to decrease the incidence of hepatocellular carcinoma.


    • 19 December 1996
      • Vol. 13  (12) , 2681-5

    Frequent microsatellite instability in post hepatitis B viral cirrhosis.

    by M Salvucci, A Lemoine, D Azoulay, M Sebagh, H Bismuth, M Reyns, E May, B Debuire

    The molecular basis of cirrhosis, the most frequent underlying liver disease in hepatocellular carcinoma, remains unclear. We investigated microsatellite instability at six different loci on chromosomes 2p, 3p, 5q, 9p, 13q and 17p, in DNA from 38 cirrhotic livers of viral (n=28) and nonviral (n=10) origin. Sixty percent of the patients exhibited microsatellite alterations in at least one chromosome locus. A striking feature was the close association between genomic instability and cirrhosis linked to hepatitis B viral infection (P<0.01). This high instability may be a clue to the etiology of cancer induced by the hepatitis B virus.


  • Molecular analysis of lymphoid malignancies

    by N Frenoy, M GilDelgado, P Pham, M Salvucci, A Chahine, A Chabli, J Misset, B Debuire

    Although lymphoid malignancies have been widely studied at the molecular level, no group has reported on the simultaneous investigation of t(14;18) chromosomal translocation, B-cell clonality and bcl2 gene expression. We have performed PCR analysis of t(14;18) translocation and B-cell clonality as well as semi-quantitation of bcl2 expression by Western blotting on a group of 41 patients treated at our institution for lymphoid malignancies. The t(14;18) translocation was observed in 10 out of 40 cases (25%) with a prevalence in the subgroup of centrofollicular lymphoma (9 out of 19, or 47%, which includes one patient in complete clinical remission). bcl2 was overexpressed in 84% of the patients (21/25) and B monoclonality was observed in 21 out of 37 B-cell neoplasia patients (57%) with or without a t(14;18) translocation. In 4 patients, bcl2 overexpression, which has been implicated in the sensitivity to a variety of cytotoxic drugs, was the only abnormality detected. Studies are currently underway to determine whether semi-quantitation of bcl2 expression provides improved prediction of a patient's response to chemotherapy.